Ezetimibe and plaque regression: Cholesterol lowering or pleiotropic effects?

Journal of the American College of Cardiology

Volumn 66, Issue 5, 2015, Pages 508-510

  Crea, Filippo ^a   Niccoli, Giampaolo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

atherosclerosis; cholesterol; ezetemibe; IVUS; plant sterols; statins

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CAMPESTEROL; CARRIER PROTEIN; EZETIMIBE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NIEMANN PICK C1 LIKE 1 PROTEIN; PHYTOSTEROL; ROSUVASTATIN; SIMVASTATIN; STEROL; UNCLASSIFIED DRUG; AZETIDINE DERIVATIVE; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE;

ACUTE CORONARY SYNDROME; ANTIINFLAMMATORY ACTIVITY; CAMPESTEROL TO CHOLESTEROL RATIO; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; COMBINATION CHEMOTHERAPY; CORONARY ARTERY ATHEROSCLEROSIS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; HUMAN; INTRAVASCULAR ULTRASOUND; MONOTHERAPY; NOTE; PERCENT ATHEROMA VOLUME; PLEIOTROPY; PRIORITY JOURNAL; STABLE ANGINA PECTORIS; UNSPECIFIED SIDE EFFECT; ATHEROSCLEROTIC PLAQUE; CORONARY ARTERY DISEASE; DYSLIPIDEMIAS; FEMALE; MALE; PERCUTANEOUS CORONARY INTERVENTION; PROCEDURES;

AZETIDINES; CORONARY ARTERY DISEASE; DYSLIPIDEMIAS; FEMALE; HEPTANOIC ACIDS; HUMANS; MALE; PERCUTANEOUS CORONARY INTERVENTION; PLAQUE, ATHEROSCLEROTIC; PYRROLES;

EID: 84938085960     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2015.05.064     Document Type: Editorial

References (19)

1. J. Perk, G. De Backer, H. Gohlke, and et al. The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts) Eur Heart J 33 2012 1635 1701
2. C. Baigent, L. Blackwell, J. Emberson, et al. for the Cholesterol Treatment Trialists' (CTT) Collaboration Efficacy and safety of more intensive lowering of LDL cholesterol: a metaanalysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
3. N.J. Stone, J. Robinson, A.H. Lichtenstein, and et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 63 2014 2889 2934
4. P. Libby How does lipid lowering prevent coronary events? New insights from human imaging trials Eur Heart J 36 2015 472 474
5. S.J. Nicholls, A. Hsu, K. Wolski, and et al. Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome J Am Coll Cardiol 55 2010 2399 2407
6. K. Tsujita, S. Sugiyama, H. Sumida, and et al. Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial J Am Coll Cardiol 66 2015 495 507
7. S.J. Nicholls, C.M. Ballantyne, P.J. Barter, and et al. Effect of two intensive statin regimens on progression of coronary disease N Engl J Med 365 2011 2078 2087
8. S.P. Barbosa, L.C. Lins, F.A. Fonseca, and et al. Effects of ezetimibe on markers of synthesis and absorption of cholesterol in high-risk patients with elevated C-reactive protein Life Sci 92 2013 845 851
9. S.B. Patel Ezetimibe: a novel cholesterol-lowering agent that highlights novel physiologic pathways Curr Cardiol Rep 6 2004 439 442
10. B. Genser, G. Silbernagel, G. De Backer, and et al. Plant sterols and cardiovascular disease: a systematic review and meta-analysis Eur Heart J 33 2012 444 451
11. B. Vergès, and F. Fumeron Potential risks associated with increased plasma plant-sterol levels Diabetes Metab 41 2015 76 81
12. Z. Sternberg, T. Chichelli, D. Sternberg, and et al. Quantitative and qualitative pleiotropic differences between simvastatin single and Vytorin combination therapy in hypercholesterolemic subjects Atherosclerosis 231 2013 411 420
13. P. Munoz-Pacheco, A. Ortega-Hernandez, M. Miana, and et al. Ezetimibe inhibits PMA-induced monocyte/macrophage differentiation by altering microRNA expression: a novel anti-atherosclerotic mechanism Pharmacol Res 66 2012 536 543
14. L. Qin, Y.B. Yang, Y.X. Yang, and et al. Inhibition of smooth muscle cell proliferation by ezetimibe via the cyclin D1-MAPK pathway J Pharmacol Sci 125 2014 283 291
15. O. Hussein, L. Minasian, Y. Itzkovich, and et al. Ezetimibe's effect on platelet aggregation and LDL tendency to peroxidation in hypercholesterolaemia as monotherapy or in addition to simvastatin Br J Clin Pharmacol 65 2008 637 645
16. Y. Kataoka, R. Puri, M. Hammadah, and et al. Cholesterol crystals associate with coronary plaque vulnerability in-vivo J Am Coll Cardiol 65 2015 630 632
17. P. Duewell, H. Kono, K.J. Rayner, and et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals Nature 464 2010 1357 1361
18. V.P. Kotaru, G. Abela, A. Janoudi, and et al. Cholesterol lowering with simvastatin and ezetimibe inhibits cholesterol crystal formation and associated inflammation (abstr) J Am Coll Cardiol 63 Suppl S 2014 A398
19. C.P. Cannon, M.A. Blazing, R.P. Giugliano, and et al. Ezetimibe added to statin therapy after acute coronary syndromes N Engl J Med 372 2015 2387 2397